PL372930A1 - N-{[(2s)-4- (3,4-difluorobenzyl) morpholin-2yl] methyl} -2-{3-[(methylsulphonyl) amino] phenyl} acetamide as ccr3 antagonist for the treatment of inflammatory conditions - Google Patents

N-{[(2s)-4- (3,4-difluorobenzyl) morpholin-2yl] methyl} -2-{3-[(methylsulphonyl) amino] phenyl} acetamide as ccr3 antagonist for the treatment of inflammatory conditions

Info

Publication number
PL372930A1
PL372930A1 PL03372930A PL37293003A PL372930A1 PL 372930 A1 PL372930 A1 PL 372930A1 PL 03372930 A PL03372930 A PL 03372930A PL 37293003 A PL37293003 A PL 37293003A PL 372930 A1 PL372930 A1 PL 372930A1
Authority
PL
Poland
Prior art keywords
methylsulphonyl
difluorobenzyl
morpholin
acetamide
phenyl
Prior art date
Application number
PL03372930A
Other languages
English (en)
Polish (pl)
Inventor
Rachael Ann Ancliff
Caroline Mary Cook
Colin David Eldred
Paul Martin Gore
Lee Andrew Harrison
Martin Alistair Hayes
Simon Teanby Hodgson
Duncan Bruce Judd
Suzanne Elaine Keeling
Xiao Qing Lewell
Gail Mills
Graeme Michael Robertson
Stephen Swanson
Andrew John Walker
Mark Wilkinson
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of PL372930A1 publication Critical patent/PL372930A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL03372930A 2002-03-28 2003-03-27 N-{[(2s)-4- (3,4-difluorobenzyl) morpholin-2yl] methyl} -2-{3-[(methylsulphonyl) amino] phenyl} acetamide as ccr3 antagonist for the treatment of inflammatory conditions PL372930A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0207449.0A GB0207449D0 (en) 2002-03-28 2002-03-28 Novel compounds

Publications (1)

Publication Number Publication Date
PL372930A1 true PL372930A1 (en) 2005-08-08

Family

ID=9933998

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372930A PL372930A1 (en) 2002-03-28 2003-03-27 N-{[(2s)-4- (3,4-difluorobenzyl) morpholin-2yl] methyl} -2-{3-[(methylsulphonyl) amino] phenyl} acetamide as ccr3 antagonist for the treatment of inflammatory conditions

Country Status (22)

Country Link
US (1) US20060058299A1 (enExample)
EP (1) EP1487453B1 (enExample)
JP (1) JP4490110B2 (enExample)
KR (1) KR20040095347A (enExample)
CN (1) CN1642553A (enExample)
AR (1) AR039177A1 (enExample)
AT (1) ATE454892T1 (enExample)
AU (1) AU2003216905A1 (enExample)
BR (1) BR0308719A (enExample)
CA (1) CA2479910A1 (enExample)
DE (1) DE60330952D1 (enExample)
ES (1) ES2339436T3 (enExample)
GB (1) GB0207449D0 (enExample)
IL (1) IL163648A0 (enExample)
IS (1) IS7415A (enExample)
MX (1) MXPA04009458A (enExample)
NO (1) NO20044098L (enExample)
PL (1) PL372930A1 (enExample)
RU (1) RU2004126145A (enExample)
TW (1) TW200400823A (enExample)
WO (1) WO2003082291A1 (enExample)
ZA (1) ZA200406990B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028530A1 (en) 2002-09-26 2004-04-08 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
JP2009501792A (ja) * 2005-07-21 2009-01-22 アストラゼネカ・アクチエボラーグ ケモカイン受容体のモジュレーターとしてのn−ベンジル−モルホリン誘導体
HUP0500877A2 (en) * 2005-09-22 2007-05-29 Sanofi Aventis Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use and intermediates
HUP0500886A2 (en) * 2005-09-23 2007-05-29 Sanofi Aventis Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use
WO2007034252A1 (en) * 2005-09-22 2007-03-29 Sanofi-Aventis Amino-alkyl-amide derivatives as ccr3 receptor liquids
HUP0800478A2 (en) * 2008-07-31 2010-03-01 Sanofi Aventis Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands
WO2013079696A1 (en) * 2011-12-01 2013-06-06 Glaxo Group Limited Methods of treatment and prevention of eye diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS562929A (en) * 1979-06-21 1981-01-13 Sumitomo Chem Co Ltd Preparation of optically active cyclopentenolone
US4870074A (en) * 1986-04-30 1989-09-26 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, for enhancing gastrointestinal motility
JPH01117882A (ja) * 1987-10-30 1989-05-10 Dainippon Pharmaceut Co Ltd 複素環式カルボン酸アミド誘導体
JPH03291274A (ja) * 1990-04-09 1991-12-20 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法
JPH04270272A (ja) * 1991-02-25 1992-09-25 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法
TW223629B (enExample) * 1992-03-06 1994-05-11 Hoffmann La Roche
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
US6031097A (en) * 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
AU2056800A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
ATE254620T1 (de) * 1999-09-14 2003-12-15 Aventis Pharma Inc Unsubstituierte ethyl- und propylderivate von phenoxythienoisoxazolen als d4 antagonisten
CZ20031195A3 (cs) * 2000-09-29 2003-09-17 Glaxo Group Limited Morfolinacetamidové deriváty
ES2275729T3 (es) * 2000-09-29 2007-06-16 Glaxo Group Limited Compuestos utiles en el tratamiento de enfermedades inflamatorias.

Also Published As

Publication number Publication date
CN1642553A (zh) 2005-07-20
RU2004126145A (ru) 2005-06-27
CA2479910A1 (en) 2003-10-09
KR20040095347A (ko) 2004-11-12
ATE454892T1 (de) 2010-01-15
NO20044098L (no) 2004-10-04
IS7415A (is) 2004-08-19
JP4490110B2 (ja) 2010-06-23
IL163648A0 (en) 2005-12-18
GB0207449D0 (en) 2002-05-08
DE60330952D1 (de) 2010-03-04
ZA200406990B (en) 2005-11-08
BR0308719A (pt) 2005-01-04
ES2339436T3 (es) 2010-05-20
AU2003216905A1 (en) 2003-10-13
JP2005525390A (ja) 2005-08-25
EP1487453A1 (en) 2004-12-22
EP1487453B1 (en) 2010-01-13
AR039177A1 (es) 2005-02-09
US20060058299A1 (en) 2006-03-16
WO2003082291A1 (en) 2003-10-09
TW200400823A (en) 2004-01-16
MXPA04009458A (es) 2005-07-27

Similar Documents

Publication Publication Date Title
PL371527A1 (en) Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterial, related compositions and methods
PL374436A1 (en) Novel polymorph of n-methyl-n-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
ZA200508905B (en) N-acyl nitrogen heterocycles as ligands of peroxisome prollferator-activated receptors
ATE361279T1 (de) N-[phenyl(piperidin-2-yl)methyl]benzamidderivat , verfahren zu ihrer herstellung und ihre therapeutische anwendung
IL164608A0 (en) 2-(2,6-Dichlorophenyl)-diarylimidazoles
WO2004004665A3 (en) Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
PL375696A1 (en) Sustained-release table composition of pramipexole
EE05362B1 (et) Aniliini derivaadid, mis on kasulikud kui fosfodiesteraas 4 inhibiitorid
AU2003229772A1 (en) Derivatives of 2-(1-benzyl-1h-pyrazolo (3, 4-b)pyridine-3yl) -5-(4-pyridinyl)-4-pyrimidine amine and the use thereof as guanylate cyclase stimulators
EG23127A (en) Novel funcidal compositions based on pyridylmethylbenzamide derivatives and imidazoline oxazolidine
PL374589A1 (en) 8/17 heterocyclic compounds and uses thereof as d-alanyl-d-alanine ligase inhibitors
AU2003274462A8 (en) N-(indole-2-carbonyl) amides as anti-diabetic agents
ZA200509103B (en) Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamideor salts thereof
AU2003223637A1 (en) Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
PL372930A1 (en) N-{[(2s)-4- (3,4-difluorobenzyl) morpholin-2yl] methyl} -2-{3-[(methylsulphonyl) amino] phenyl} acetamide as ccr3 antagonist for the treatment of inflammatory conditions
ATE381263T1 (de) Fungizide zusammensetzungen, die n-(alpha-cyano-2-thenyl)-4-ethyl-2-ethylamino-5 thiazolcarboxamide enthalten
IL213960A0 (en) 2-(substituted phenyl)-2-hydroxyl -ethyl carbamates
HRP20040920A2 (en) Novel form of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
EP1558574A4 (en) NEW N-HYDROXYTHINO, UREA-AND-AMIDE COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
PT1545710E (pt) Utilização de n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil) piridino-3-sulfonamida no tratamento de cancro
TW200507755A (en) Fungicidal mixtures
AU2003235814A8 (en) Novel process for the preparation of trans-3- ethyl-2,5- dihydro-4- methyl-n-(2-( 4-(((((4-methyl cyclohexyl) amino)carbonyl) amino)sulfonyl) phenyl)ethyl) -2-oxo-1h-pyrrole -1-carboxamide
HK1071699A (en) N-[(2s)-4-(3,4-difluorobenzyl)morpholin-2-yl]methyl-2-3-[(methylsulphonyl)amino]phenyl acetamide as ccr3 antagonist for the treatment of inflammatory conditions
PL377708A1 (pl) Oksazole jako wzmacniacze mGluR1
PL373280A1 (en) Process for the preparation of modification i of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)